Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 78 entries
Sorted by: Best Match Show Resources per page
DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant.

Vaccines

Nyström S, Bråve A, Falkeborn T, Devito C, Rissiek B, Johansson DX, Schröder U, Uematsu S, Akira S, Hinkula J, Applequist SE.
PMID: 26344341
Vaccines (Basel). 2013 Sep 25;1(4):415-43. doi: 10.3390/vaccines1040415.

Eliciting effective immune responses using non-living/replicating DNA vaccines is a significant challenge. We have previously shown that ballistic dermal plasmid DNA-encoded flagellin (FliC) promotes humoral as well as cellular immunity to co-delivered antigens. Here, we observe that a plasmid...

Cite
Nyström S, Bråve A, Falkeborn T, et al. DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant. Vaccines (Basel). 2013;1(4):415-43doi: 10.3390/vaccines1040415.
Nyström, S., Bråve, A., Falkeborn, T., Devito, C., Rissiek, B., Johansson, D. X., Schröder, U., Uematsu, S., Akira, S., Hinkula, J., & Applequist, S. E. (2013). DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant. Vaccines, 1(4), 415-43. https://doi.org/10.3390/vaccines1040415
Nyström, Sanna, et al. "DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant." Vaccines vol. 1,4 (2013): 415-43. doi: https://doi.org/10.3390/vaccines1040415
Nyström S, Bråve A, Falkeborn T, Devito C, Rissiek B, Johansson DX, Schröder U, Uematsu S, Akira S, Hinkula J, Applequist SE. DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant. Vaccines (Basel). 2013 Sep 25;1(4):415-43. doi: 10.3390/vaccines1040415. PMID: 26344341; PMCID: PMC4494208.
Copy Download .nbib Format: NLM
Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies.

Seminars in interventional radiology

Nguyen HL, Boon LM, Vikkula M.
PMID: 28955112
Semin Intervent Radiol. 2017 Sep;34(3):233-238. doi: 10.1055/s-0037-1604296. Epub 2017 Sep 11.

Vascular anomalies arise as a consequence of improper development and maintenance of the vasculature. Our knowledge on the pathophysiological bases of vascular anomalies has skyrocketed during the past 5 years. It is becoming clear that common intracellular signaling pathways...

Cite
Nguyen HL, Boon LM, Vikkula M. Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies. Semin Intervent Radiol. 2017;34(3):233-238doi: 10.1055/s-0037-1604296.
Nguyen, H. L., Boon, L. M., & Vikkula, M. (2017). Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies. Seminars in interventional radiology, 34(3), 233-238. https://doi.org/10.1055/s-0037-1604296
Nguyen, Ha-Long, et al. "Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies." Seminars in interventional radiology vol. 34,3 (2017): 233-238. doi: https://doi.org/10.1055/s-0037-1604296
Nguyen HL, Boon LM, Vikkula M. Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies. Semin Intervent Radiol. 2017 Sep;34(3):233-238. doi: 10.1055/s-0037-1604296. Epub 2017 Sep 11. PMID: 28955112; PMCID: PMC5615384.
Copy Download .nbib Format: NLM
Inflammatory versus malignant middle lobe disease.

Annales chirurgiae et gynaecologiae Fenniae

VIRKKULA L.
PMID: 13781550
Ann Chir Gynaecol Fenn. 1961;50:88-96.

No abstract available.

Cite
VIRKKULA L. Inflammatory versus malignant middle lobe disease. Ann Chir Gynaecol Fenn. 1961;50:88-96
VIRKKULA, L. (1961). Inflammatory versus malignant middle lobe disease. Annales chirurgiae et gynaecologiae Fenniae, 5088-96.
VIRKKULA, L. "Inflammatory versus malignant middle lobe disease." Annales chirurgiae et gynaecologiae Fenniae vol. 50 (1961): 88-96.
VIRKKULA L. Inflammatory versus malignant middle lobe disease. Ann Chir Gynaecol Fenn. 1961;50:88-96. PMID: 13781550.
Copy Download .nbib Format: NLM
Molecular basis of vascular anomalies.

Trends in cardiovascular medicine

Vikkula M, Boon LM, Mulliken JB, Olsen BR.
PMID: 14987552
Trends Cardiovasc Med. 1998 Oct;8(7):281-92. doi: 10.1016/s1050-1738(98)00024-3.

Vascular anomalies comprise a heterogeneous group of disorders that are divided into tumors (hemangiomas) and malformations. Recent advances in biomedical research provide insights into the molecular basis of these disorders and a deeper understanding of vascular morphogenesis. In the...

Cite
Vikkula M, Boon LM, Mulliken JB, et al. Molecular basis of vascular anomalies. Trends Cardiovasc Med. 1998;8(7):281-92doi: 10.1016/s1050-1738(98)00024-3.
Vikkula, M., Boon, L. M., Mulliken, J. B., & Olsen, B. R. (1998). Molecular basis of vascular anomalies. Trends in cardiovascular medicine, 8(7), 281-92. https://doi.org/10.1016/s1050-1738(98)00024-3
Vikkula, M, et al. "Molecular basis of vascular anomalies." Trends in cardiovascular medicine vol. 8,7 (1998): 281-92. doi: https://doi.org/10.1016/s1050-1738(98)00024-3
Vikkula M, Boon LM, Mulliken JB, Olsen BR. Molecular basis of vascular anomalies. Trends Cardiovasc Med. 1998 Oct;8(7):281-92. doi: 10.1016/s1050-1738(98)00024-3. PMID: 14987552.
Copy Download .nbib Format: NLM
Sensibility threshold in depressive and nondepressive patients with chronic orofacial pain.

Anesthesia progress

Hampf G, Aalberg V, Ekholm A, Vikkula J.
PMID: 19598700
Anesth Prog. 1988 Jul;35(4):152-4.

Sensibility threshold was measured in patients with depressive and nondepressive psychiatric disorders, where both groups were suffering from chronic orofacial pain. The control patients had no pain and no signs of mental disturbance. Patients with major depressive disorders had...

Cite
Hampf G, Aalberg V, Ekholm A, et al. Sensibility threshold in depressive and nondepressive patients with chronic orofacial pain. Anesth Prog. 1988;35(4):152-4
Hampf, G., Aalberg, V., Ekholm, A., & Vikkula, J. (1988). Sensibility threshold in depressive and nondepressive patients with chronic orofacial pain. Anesthesia progress, 35(4), 152-4.
Hampf, G, et al. "Sensibility threshold in depressive and nondepressive patients with chronic orofacial pain." Anesthesia progress vol. 35,4 (1988): 152-4.
Hampf G, Aalberg V, Ekholm A, Vikkula J. Sensibility threshold in depressive and nondepressive patients with chronic orofacial pain. Anesth Prog. 1988 Jul;35(4):152-4. PMID: 19598700; PMCID: PMC2167958.
Copy Download .nbib Format: NLM
Acetylcholine and an acetylcholinesterase inhibitor neostigmine can aggravate tularemia progress in BALB/c mice.

Interdisciplinary toxicology

Pohanka M, Pavlis O, Svobodova H, Pikula J.
PMID: 22783145
Interdiscip Toxicol. 2012 Mar;5(1):21-4. doi: 10.2478/v10102-012-0004-7.

The present experiment was aimed at assessing the application of neostigmine, an acetylcholinesterase (AChE) pseudo-irreversible inhibitor with poor penetration through the hematoencephalitic barrier, and the neurotransmitter acetylcholine (ACh). The experiment was done to evaluate their ability to modulate an...

Cite
Pohanka M, Pavlis O, Svobodova H, et al. Acetylcholine and an acetylcholinesterase inhibitor neostigmine can aggravate tularemia progress in BALB/c mice. Interdiscip Toxicol. 2012;5(1):21-4doi: 10.2478/v10102-012-0004-7.
Pohanka, M., Pavlis, O., Svobodova, H., & Pikula, J. (2012). Acetylcholine and an acetylcholinesterase inhibitor neostigmine can aggravate tularemia progress in BALB/c mice. Interdisciplinary toxicology, 5(1), 21-4. https://doi.org/10.2478/v10102-012-0004-7
Pohanka, Miroslav, et al. "Acetylcholine and an acetylcholinesterase inhibitor neostigmine can aggravate tularemia progress in BALB/c mice." Interdisciplinary toxicology vol. 5,1 (2012): 21-4. doi: https://doi.org/10.2478/v10102-012-0004-7
Pohanka M, Pavlis O, Svobodova H, Pikula J. Acetylcholine and an acetylcholinesterase inhibitor neostigmine can aggravate tularemia progress in BALB/c mice. Interdiscip Toxicol. 2012 Mar;5(1):21-4. doi: 10.2478/v10102-012-0004-7. PMID: 22783145; PMCID: PMC3389505.
Copy Download .nbib Format: NLM
Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema.

Molecular syndromology

Mendola A, Schlögel MJ, Ghalamkarpour A, Irrthum A, Nguyen HL, Fastré E, Bygum A, van der Vleuten C, Fagerberg C, Baselga E, Quere I, Mulliken JB, Boon LM, Brouillard P, Vikkula M.
PMID: 24167460
Mol Syndromol. 2013 Sep;4(6):257-66. doi: 10.1159/000354097. Epub 2013 Aug 21.

Lymphedema is caused by dysfunction of lymphatic vessels, leading to disabling swelling that occurs mostly on the extremities. Lymphedema can be either primary (congenital) or secondary (acquired). Familial primary lymphedema commonly segregates in an autosomal dominant or recessive manner....

Cite
Mendola A, Schlögel MJ, Ghalamkarpour A, et al. Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema. Mol Syndromol. 2013;4(6):257-66doi: 10.1159/000354097.
Mendola, A., Schlögel, M. J., Ghalamkarpour, A., Irrthum, A., Nguyen, H. L., Fastré, E., Bygum, A., van der Vleuten, C., Fagerberg, C., Baselga, E., Quere, I., Mulliken, J. B., Boon, L. M., Brouillard, P., Vikkula, M. (2013). Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema. Molecular syndromology, 4(6), 257-66. https://doi.org/10.1159/000354097
Mendola, A, et al. "Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema." Molecular syndromology vol. 4,6 (2013): 257-66. doi: https://doi.org/10.1159/000354097
Mendola A, Schlögel MJ, Ghalamkarpour A, Irrthum A, Nguyen HL, Fastré E, Bygum A, van der Vleuten C, Fagerberg C, Baselga E, Quere I, Mulliken JB, Boon LM, Brouillard P, Vikkula M. Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema. Mol Syndromol. 2013 Sep;4(6):257-66. doi: 10.1159/000354097. Epub 2013 Aug 21. PMID: 24167460; PMCID: PMC3776465.
Copy Download .nbib Format: NLM
Physiological and autonomic stress responses after prolonged sleep restriction and subsequent recovery sleep in healthy young men.

Sleep and biological rhythms

van Leeuwen WMA, Sallinen M, Virkkala J, Lindholm H, Hirvonen A, Hublin C, Porkka-Heiskanen T, Härmä M, Fisk R.
PMID: 29367834
Sleep Biol Rhythms. 2018;16(1):45-54. doi: 10.1007/s41105-017-0122-x. Epub 2017 Sep 08.

PURPOSE: Sleep restriction is increasingly common and associated with the development of health problems. We investigated how the neuroendocrine stress systems respond to prolonged sleep restriction and subsequent recovery sleep in healthy young men.METHODS: After two baseline (BL) nights...

Cite
van Leeuwen WMA, Sallinen M, Virkkala J, et al. Physiological and autonomic stress responses after prolonged sleep restriction and subsequent recovery sleep in healthy young men. Sleep Biol Rhythms. 2017;16(1):45-54doi: 10.1007/s41105-017-0122-x.
van Leeuwen, W. M. A., Sallinen, M., Virkkala, J., Lindholm, H., Hirvonen, A., Hublin, C., Porkka-Heiskanen, T., Härmä, M., & Fisk, R. (2018). Physiological and autonomic stress responses after prolonged sleep restriction and subsequent recovery sleep in healthy young men. Sleep and biological rhythms, 16(1), 45-54. https://doi.org/10.1007/s41105-017-0122-x
van Leeuwen, Wessel M A, et al. "Physiological and autonomic stress responses after prolonged sleep restriction and subsequent recovery sleep in healthy young men." Sleep and biological rhythms vol. 16,1 (2018): 45-54. doi: https://doi.org/10.1007/s41105-017-0122-x
van Leeuwen WMA, Sallinen M, Virkkala J, Lindholm H, Hirvonen A, Hublin C, Porkka-Heiskanen T, Härmä M, Fisk R. Physiological and autonomic stress responses after prolonged sleep restriction and subsequent recovery sleep in healthy young men. Sleep Biol Rhythms. 2018;16(1):45-54. doi: 10.1007/s41105-017-0122-x. Epub 2017 Sep 08. PMID: 29367834; PMCID: PMC5754428.
Copy Download .nbib Format: NLM
Tissue metallothionein response in the Japanese quail associated with exposure to cyanobacterial biomass, lead and the Newcastle disease virus.

Neuro endocrinology letters

Kovacova V, Piacek V, Abdelsalam EEE, Bandouchova H, Heger T, Kobelkova K, Sedlackova J, Vitula F, Pikula J.
PMID: 30927762
Neuro Endocrinol Lett. 2019 Mar;39(8):567-571.

OBJECTIVES: Here we tested the hypothesis that multiple toxic and infectious stressors combine in their adverse effects to produce higher tissue responses of metallothioneins (MTs) in birds.METHODS: We used Japanese quails as a model avian species. The study is...

Cite
Kovacova V, Piacek V, Abdelsalam EEE, et al. Tissue metallothionein response in the Japanese quail associated with exposure to cyanobacterial biomass, lead and the Newcastle disease virus. Neuro Endocrinol Lett. 2019;39(8):567-571
Kovacova, V., Piacek, V., Abdelsalam, E. E. E., Bandouchova, H., Heger, T., Kobelkova, K., Sedlackova, J., Vitula, F., & Pikula, J. (2019). Tissue metallothionein response in the Japanese quail associated with exposure to cyanobacterial biomass, lead and the Newcastle disease virus. Neuro endocrinology letters, 39(8), 567-571.
Kovacova, Veronika, et al. "Tissue metallothionein response in the Japanese quail associated with exposure to cyanobacterial biomass, lead and the Newcastle disease virus." Neuro endocrinology letters vol. 39,8 (2019): 567-571.
Kovacova V, Piacek V, Abdelsalam EEE, Bandouchova H, Heger T, Kobelkova K, Sedlackova J, Vitula F, Pikula J. Tissue metallothionein response in the Japanese quail associated with exposure to cyanobacterial biomass, lead and the Newcastle disease virus. Neuro Endocrinol Lett. 2019 Mar;39(8):567-571. PMID: 30927762.
Copy Download .nbib Format: NLM
Letter: Is Developmental Venous Anomaly an Imaging Biomarker of PIK3CA Mutated Gliomas?.

Neurosurgery

Roux A, Vikkula M, Pallud J.
PMID: 31742343
Neurosurgery. 2020 Jan 01;86(1):E93. doi: 10.1093/neuros/nyz425.

No abstract available.

Cite
Roux A, Vikkula M, Pallud J. Letter: Is Developmental Venous Anomaly an Imaging Biomarker of PIK3CA Mutated Gliomas?. Neurosurgery. 2020;86(1):E93doi: 10.1093/neuros/nyz425.
Roux, A., Vikkula, M., & Pallud, J. (2020). Letter: Is Developmental Venous Anomaly an Imaging Biomarker of PIK3CA Mutated Gliomas?. Neurosurgery, 86(1), E93. https://doi.org/10.1093/neuros/nyz425
Roux, Alexandre, et al. "Letter: Is Developmental Venous Anomaly an Imaging Biomarker of PIK3CA Mutated Gliomas?." Neurosurgery vol. 86,1 (2020): E93. doi: https://doi.org/10.1093/neuros/nyz425
Roux A, Vikkula M, Pallud J. Letter: Is Developmental Venous Anomaly an Imaging Biomarker of PIK3CA Mutated Gliomas?. Neurosurgery. 2020 Jan 01;86(1):E93. doi: 10.1093/neuros/nyz425. PMID: 31742343.
Copy Download .nbib Format: NLM
Fluctuations of focused electron beam in a conventional SEM.

Ultramicroscopy

Knápek A, Šikula J, Bartlová M.
PMID: 31128413
Ultramicroscopy. 2019 Sep;204:49-54. doi: 10.1016/j.ultramic.2019.05.008. Epub 2019 May 20.

Noise diagnostics was performed on a tungsten hairpin cathode that was used in conventional scanning electron microscope (SEM) which operates in a high vacuum. The focused beam was firstly measured and its power spectrum obtained in order to characterize...

Cite
Knápek A, Šikula J, Bartlová M. Fluctuations of focused electron beam in a conventional SEM. Ultramicroscopy. 2019;204:49-54doi: 10.1016/j.ultramic.2019.05.008.
Knápek, A., Šikula, J., & Bartlová, M. (2019). Fluctuations of focused electron beam in a conventional SEM. Ultramicroscopy, 20449-54. https://doi.org/10.1016/j.ultramic.2019.05.008
Knápek, Alexandr, et al. "Fluctuations of focused electron beam in a conventional SEM." Ultramicroscopy vol. 204 (2019): 49-54. doi: https://doi.org/10.1016/j.ultramic.2019.05.008
Knápek A, Šikula J, Bartlová M. Fluctuations of focused electron beam in a conventional SEM. Ultramicroscopy. 2019 Sep;204:49-54. doi: 10.1016/j.ultramic.2019.05.008. Epub 2019 May 20. PMID: 31128413.
Copy Download .nbib Format: NLM
Correction to: Cognitive behavioural therapy interventions for insomnia among shift workers: RCT in an occupational health setting.

International archives of occupational and environmental health

Järnefelt H, Härmä M, Sallinen M, Virkkala J, Paajanen T, Martimo KP, Hublin C.
PMID: 32125525
Int Arch Occup Environ Health. 2020 Jul;93(5):551. doi: 10.1007/s00420-020-01527-4.

In the original publication of the article, the first name and last name of the authors were interchanged.

Cite
Järnefelt H, Härmä M, Sallinen M, et al. Correction to: Cognitive behavioural therapy interventions for insomnia among shift workers: RCT in an occupational health setting. Int Arch Occup Environ Health. 2020;93(5):551doi: 10.1007/s00420-020-01527-4.
Järnefelt, H., Härmä, M., Sallinen, M., Virkkala, J., Paajanen, T., Martimo, K. P., & Hublin, C. (2020). Correction to: Cognitive behavioural therapy interventions for insomnia among shift workers: RCT in an occupational health setting. International archives of occupational and environmental health, 93(5), 551. https://doi.org/10.1007/s00420-020-01527-4
Järnefelt, Heli, et al. "Correction to: Cognitive behavioural therapy interventions for insomnia among shift workers: RCT in an occupational health setting." International archives of occupational and environmental health vol. 93,5 (2020): 551. doi: https://doi.org/10.1007/s00420-020-01527-4
Järnefelt H, Härmä M, Sallinen M, Virkkala J, Paajanen T, Martimo KP, Hublin C. Correction to: Cognitive behavioural therapy interventions for insomnia among shift workers: RCT in an occupational health setting. Int Arch Occup Environ Health. 2020 Jul;93(5):551. doi: 10.1007/s00420-020-01527-4. PMID: 32125525; PMCID: PMC7260145.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 78 entries